Rim Research In Medicine is categorized under Internal Medicine Doctors in Toms River, NJ and active since 2000.
Rim Research In Medicine was established in 2000, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Internal Medicine Doctors business, which does work in the B2C market, and is classified as a Internal Medicine Doctors, under code number 621111 by the NAICS.
If you are seeking more information, feel free to contact Gerard Clendenin at the company’s single location by writing to 2140 10th Avenue, Toms River, New Jersey NJ 08757 or by phoning (732) 349-2940. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Rim Research In Medicine |
| Contact Person: | Gerard Clendenin |
| Address: | 2140 10th Avenue, Toms River, New Jersey 08757 |
| Phone Number: | (732) 349-2940 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2000 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Internal Medicine Doctors |
| SIC Code: | 8011 |
| NAICS Code: | 621111 |
| Share This Business: |
Rim Research In Medicine was started in 2000 to provide professional Internal Medicine Doctors under the SIC code 8011 and NAICS code 621111. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Gerard Clendenin for inquiries that concern Rim Research In Medicine by calling the company number (732) 349-2940, as your correspondence is most welcome. Additionally, the physical location of the single location of Rim Research In Medicine can be found at the coordinates 40.004518,-74.240186 as well as the street address 2140 10th Avenue in Toms River, New Jersey 08757.
For its online presence, you may visit Rim Research In Medicine’s website at and engage with its social media outlets through on Twitter and on Facebook.